Thomas G. Lynch is Director at Evofem Biosciences, Inc. (EVFM). They have made 1 open-market trade across 1 company since 2018, most recently 2020-03-31.
CIK 0001360000
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $452K since 2018, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EVFM | 325,000 | $155K |
Shares reported on the most recent Form 4, priced at the 2020-04-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EVFM | BUY | 2018-08-14 | 2018-08-15 | $2.26 | $452K | +5.5% | +65.9% | +54.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.